Clover Biopharmaceuticals and Adimmune have signed an exclusive agreement to commercialise the latter’s AdimFlu-S (QIS) influenza vaccine in mainland China.
Under the deal, Clover will also have exclusive rights to commercialise the influenza vaccine in Brazil, Bangladesh, and the Philippines, upon receipt of regulatory approvals.
The company will also get an opportunity to collaborate with Adimmune to develop additional vaccine candidates, including next-generation vaccines for influenza.
The quadrivalent split-inactivated vaccine AdimFlu-S (QIS) has been developed to prevent influenza.
It comprises hemagglutinin from four strains of influenza virus (two A and two B), so the vaccine has the potential to show high effectiveness against seasonal influenza vaccine relative to trivalent options.
In January last year, the China National Medical Products Administration (NMPA) approved the vaccine for individuals aged three years and above.
AdimFlu-S (QIS) is claimed to be the only imported quadrivalent seasonal influenza vaccine approved in the country.
It is expected to be launched in the second half of this year.
Clover CEO and executive director Joshua Liang said: “We are delighted to form this strategic partnership with Adimmune, a company with a stellar track record in manufacturing and supplying critical vaccines to populations in Asia, particularly as the market for flu vaccines generally, and quadrivalent vaccines specifically, is poised for significant growth in mainland China.
“This partnership also brings Clover one step closer to establishing a leading respiratory vaccine franchise and allows us to realise synergies with the ongoing commercialisation of our Covid-19 vaccine.”
Adimmune will manufacture the vaccine at its facility that has been certified by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and many other agencies for good manufacturing practices (GMP).